Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.62 |
| ▸ | ESR1 | P03372 | 6/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9956928 | 0.91 | ESR1 (0.57) | CYP19A1ESR1ESR2 | |
| SCHEMBL17728326 | 0.88 | CYP19A1 (0.48) | CYP19A1ESR1ESR2MAOAMAOB | |
| Trifluoroacetic Acid SCHEMBL17728325 | 0.86 | ESR1 (0.52) | CYP19A1ESR1ESR2 | |
| SCHEMBL8934606 | 0.83 | CYP19A1 (0.80) | CYP19A1ESR1ESR2ALDH1A1CYP1A2 | |
| SCHEMBL5142252 | 0.79 | CYP19A1 (0.74) | CYP19A1ESR1ESR2ALDH1A1CYP1A2 | |
| SCHEMBL17900008 | 0.78 | CYP19A1 (0.38) | CYP19A1ESR1MAOAMAOBDRD2 | |
| SCHEMBL13183965 | 0.77 | CYP19A1 (0.67) | CYP19A1ESR1ESR2ALDH1A1CYP1A2 | |
| SCHEMBL14428676 | 0.76 | CYP19A1 (0.68) | CYP19A1ESR1ESR2ALDH1A1CYP1A2 | |
| SCHEMBL8934551 | 0.75 | VKORC1 (0.66) | CYP19A1ESR1ESR2MAOBALDH1A1 | |
| SCHEMBL5428058 | 0.72 | CYP19A1 (0.81) | CYP19A1ESR1ESR2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540361-B2 | N-substituted azetidine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2017-01-10 | — | — | US | disclosed |
| US-9540361-B2 | N-substituted azetidine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2017-01-10 | — | — | US | disclosed |
| US-9540361-B2 | N-substituted azetidine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2017-01-10 | — | — | US | disclosed |
| EP-2655367-B1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2016-07-06 | — | — | EP | disclosed |
| EP-2655367-B1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2016-07-06 | — | — | EP | disclosed |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2016-05-12 | — | — | US | disclosed |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2016-05-12 | — | — | US | disclosed |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2016-05-12 | — | — | US | disclosed |
| EP-2655367-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | Merck Sharp & Dohme B.V. (NL) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012084711-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MSD OSS B.V. (NL) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012084711-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MSD OSS B.V. (NL) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | ESR2, ESR1, GPER1 | CYP19A1 6/4885ESR1 2/4885ESR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.